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Poster Session-I 43outpatient AMD3100 administration and the usual daytime leuka-
pheresis at our center. Therefore, we received an institutional
waiver from AnorMed/Genzyme for early morning administration
of AMD3100 followed by leukapheresis approximately six hours
later for all subsequent patients. We compare here the outcomes
of the three patients with previous day (qhs) versus four patients re-
ceiving early morning (qam) administration of AMD3100. The me-
dian age, weight, # prior chemotherapy regimens, highest CD34
cells/ml achieved during most recent mobilization attempt for qhs
vs qam administration were: 58 vs 48.5 years, 80 vs. 76 kg, 2 vs
3.5, and 4.13 vs. 7.21 respectively. Of note, all three patients in
the qhs dosing had received prior radiation whereas none of the
four patients in the qam group did. The median CD34 cells/ml
24 hours prior to the first AMD3100 dose in the two groups was
3.6 vs 4.035. For each group, the median CD34 cells/ml taken im-
mediately prior to apheresis (averaged over the two to four days of
stem cell collection) was 9.22 vs. 25.7. After a median of three days
of collection in both groups, the total number of CD34 cells *106/
kg collected was 2.6 for the qhs group versus 5.57 for the qam
group. These results demonstrate (at least for patients without
prior radiation) the feasibility of a completely daytime, outpatient
peripheral blood stem cell harvest by administering AMD3100 six
hours prior to leukapheresis.108
AUTOGRAFTING IN ACUTE MYELOGENOUS LEUKEMIA: A SINGLE
CENTER EXPERIENCE
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The role of autografting for AML continues to be defined, and its
positioning in therapy as compared to allogeneic transplantation and
chemotherapy approaches is still under investigation. Between 1989
and 2008, 87 autologous stem cell transplants have been performed
at the University of Rochester Medical Center for acute myeloge-
nous leukemia. The mean age at transplant was 39 years with a range
of 2 to 67 years. All but 3 patients were Caucasian. Nine patients
were \ 18 years of age and 9 patients were above age 60 at the
time of transplant. 51% of patients were male. 59% of patients
were transplanted after marrow harvest and 41% after peripheral
blood stem cell collection. Almost all were conditioned with busulfan
and cyclophosphmide. At time of analysis (8/08), 67% of patients
were deceased, and 33% were alive. Seven patients died before day
100; 3 of infection, two of disease recurrence, and two of unknown
causes. In the remaining patients, the mean survival was 1512 6
196 days. In those still living, the mean survival is 2451 6 325 days
(median 2693 days). Of these patients, 4 have undergone allogeneic
stem cell transplantation for recurrent AML and remain in remis-
sion, and one patient received FLAG chemotherapy after a post-
transplant relapse and is still disease free 11 years later. In those
with relapsed disease, where date of relapse was known with preci-
sion, the time range for relapse was from 63 days to greater than
10 years. All but 4 relapses occurred prior to two years. In those pa-
tients who died of causes other than AML relapse, 8 had pulmonary
disease, 2 had sepsis, 3 had fungal infections, 1 had liver failure, and 1
had later onset of ovarian cancer. In 13 cases lost to follow up, the
cause of death is unknown. This single center experience demon-
strates that autologous stem cell support after high dose therapy
for treatment of acute myelogenous leukemia does result in long-
term disease remission in about one third of cases. Late relapses do
occur, and most regimen related mortality manifests early after auto-
grafting.109
CLINICAL OUTCOMES WITH AND WITHOUT SARGRAMOSTIM (GM-CSF)
POST AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTA-
TION
Howle, E.L., Wolf, R.C., Burzynski, J.A., Gastineau, D.A., Lacy, M.Q.,
Gertz, M.A., Dispenzieri, A., Kumar, S., Dingli, D., Buadi, F.,
Inwards, D.J., Ansell, S.M., Micallef, I.N.M., Johnston, P.B.,
Porrata, L.F., Elliott, M.A., Hogan, W.J., Litzow, M.R. Mayo Clinic,
Rochester, MNBackground: Colony stimulating factors (CSF) have substantial
benefits when administered following autologous bone marrow
transplant. With contemporary patient populations, conditioning
regimens and supportive care, the value of CSF administration fol-
lowing autologous peripheral blood stem cell transplant
(APBSCT) is less established. While CSF may slightly decrease
time to neutrophil engraftment, the impact on hospitalization
rate, infections and other clinical outcomes is not clear. On 4/1/
08, a consensus-based practice change eliminated the routine use
of CSF following APBSCT at Mayo Clinic Rochester based on
the hypothesis that this would not significantly impact clinical out-
comes.
Methods: Following IRB approval, a retrospective evaluation
was conducted. All adult patients who received an APBSCT be-
tween 8/1/2007 and 8/31/2008 were reviewed. Patients were ex-
cluded if they refused consent for use of medical records for
research, they received a prior transplant, their primary malig-
nancy was amyloidosis or POEMS, or if they received filgrastim
as prophylaxis following APBSCT. Baseline demographic charac-
teristics and clinical endpoints were collected including: time to
engraftment, number of transfusions, incidence of infection, fever
and duration of therapeutic antimicrobials, incidence of engr-
aftment syndrome, and duration of hospitalization and daily
follow-up.
Results:Of 259 patients reviewed, 140 were included in the anal-
ysis (n 5 66 in GM-CSF group, n 5 74 in no CSF group). 119 pa-
tients were excluded: consent refused (n 5 4), prior transplant (n
5 28), amyloidosis (n 5 38), POEMS (n 5 10), filgrastim adminis-
tered (n 5 30). The majority of patients had a primary diagnosis of
either multiple myeloma or non-Hodgkin lymphoma. Demographic
data between groups was similar. Time to neutrophil engraftment
was a median of 12 days in the GM-CSF group versus 14 days in
the no CSF group (p\0.0001). Other major hematopoietic and
infection-related clinical outcomes were not significantly different
between groups.Clinical Outcomes with and without Sargramostim (GM-CSF)
GM-CSF No CSF p-valueNeutrophil engraftment
in days (median;
interquartile range)12 (11–14) 14 (12.75–17) \0.0001Platelet engraftment
in days (median;
interquartile range)13 (12–15) 14 (12.75–15) 0.39Red blood cell transfusions
(median; interquartile
range)3 (2–4) 3 (2–4) 0.82Platelet transfusions
(median; interquartile
range)3 (2–6) 4 (2–6) 0.21Incidence of microbiologically
documented infection (%)21 32 0.14Incidence of fever (%) 77 66 0.15
Incidence of engraftment
syndrome (%)
3 5 0.49Duration of therapeutic
antimicrobials in days
(median; interquartile range)6 (1.75–8) 6 (0–8) 0.84Duration of hospitalization
in days (median; interquartile
range)2.5 (0–10) 4 (0–8) 0.66Duration of daily follow-up in
days (median; interquartile range)18 (16–21) 19 (18–23) 0.0015Conclusion: Preliminary analysis suggests that eliminating CSF
following APBSCT modestly delays neutrophil engraftment but
does not significantly impact other clinical outcomes. Analysis of
lymphocyte recovery and day 100 mortality between groups is on-
going.
